Early Evidence of Impact of Monovalent Rotavirus Vaccine in Togo

Enyonam Tsolenyanu*, Jason M. Mwenda, Anoumou Dagnra, Eyal Leshem, Mawussi Godonou, Ibrahim Nassoury, Dadja Landoh, Jacqueline E. Tate, Yawo Atakouma, Umesh D. Parashar

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Togo introduced monovalent rotavirus vaccine starting 19 June 2014. We compared all-cause acute gastroenteritis (AGE) hospitalizations and rotavirus-associated hospitalizations during the prevaccine period (July 2008-June 2014) to 1 year after vaccine introduction (July 2014-June 2015). The proportion of children with AGE who tested positive for rotavirus declined from 53% (645/1223) in prevaccine years to 36% (68/187) in the postvaccine year (P <. 01). The decline only occurred in children <1 year of age who were eligible for vaccination and was greatest during the rotavirus season months, supporting that it was associated with vaccine implementation.

Original languageEnglish
Pages (from-to)S196-S199
JournalClinical Infectious Diseases
StatePublished - 1 May 2016
Externally publishedYes


  • Togo
  • impact
  • monovalent rotavirus vaccine
  • rotavirus


Dive into the research topics of 'Early Evidence of Impact of Monovalent Rotavirus Vaccine in Togo'. Together they form a unique fingerprint.

Cite this